In addition to palpation and ultrasound examination, the PSA test has been available for the early detection of prostate carcinoma for over 25 years.

Functional magnetic resonance imaging (fMRI, magnetic resonance imaging) using a 3 Tesla tomograph is currently the most accurate method for visualizing prostate cancer.

Prostate biopsy is the removal of tissue from the prostate gland for examination by a pathologist under a microscope.

The West German Prostate Center uses the most modern imaging procedure currently available and combines this with punch biopsy.

Stockholm3 is a new type of blood test that was developed by the Karolinska Institute in Sweden and has been used successfully in Scandinavia for the early detection of prostate cancer since 2017.

In perineal prostate biopsy, tissue is removed via the patient's perineum. A grid (template) enables a pinpoint biopsy according to a predefined scheme.

The malignancy of prostate cancer depends not only on the type and extent of the tumor, but also on how different the cells of the tumor tissue are from the healthy prostate cells.

The TNM classification describes the size and extent of the tumor as well as the spread of cancer cells to other organs.

PSMA imaging with a newly developed lightly radioactive marker for PET (positron emission tomography), detects tumor sites and metastases even more precisely than

Bone scintigraphy (also known as skeletal scintigraphy) is a special nuclear medicine examination method used to visualize the metabolic activity of bones.